Progesterone 300mg Capsules

Progesterone 300mg Capsules leverage state-of-the-art micronization processing to ensure optimal clinical outcomes at a higher dosage threshold. By breaking down the active hormone crystal structures into ultra-fine particles, this technology stabilizes gastrointestinal transit and maximizes systemic bioavailability. As a bioidentical progestogen, it delivers powerful tissue-specific modulation without triggering the fluid-retaining, metabolic, or androgenic side effects common to synthetic progestins.

• High-Capacity Endometrial Regulation: In cases where patients require elevated estrogen doses, a correspondingly robust progestogen counter-balance is essential. Micronized progesterone binds directly to nuclear uterine receptors, safely halting estrogen-induced cellular proliferation and converting the endometrium into a secure, secretory architecture to eliminate hyperplastic risks.

• Central Nervous System Relaxation: Following oral intake, a significant portion of the compound metabolizes into neurosteroids such as allopregnanolone. This metabolite crosses the blood-brain barrier and operates as a potent positive allosteric modulator of central $GABA_A$ receptors, offering a pronounced calming effect on the nervous system, settling severe evening anxiety, and restoring restorative sleep cycles.

• Advanced Menopausal HRT Support: Balances high-dose or customized estrogen replacement regimens to maintain absolute endometrial lining safety in women with an intact uterus.

• Severe Secondary Amenorrhea: Induces uniform withdrawal bleeding in non-pregnant women experiencing long-term menstrual absence due to severe hypothalamic or ovarian imbalances.

• Assisted Reproductive Technology (ART): Provides intensive luteal phase support during high-risk In Vitro Fertilization (IVF) transfers to optimize uterine lining receptivity.

• Dysfunctional Uterine Bleeding Management: Controls and stabilizes erratic, heavy bleeding episodes by restoring structural progestational balance to the menstrual cycle.

Clinical Advantages & Key Benefits

• Bioidentical Molecular Fidelity: Chemically identical to native human progesterone, ensuring high cellular affinity and an exceptionally clean physiological response.

• Dual Administration Pathways: Formulated within specialized soft gelatin shells, allowing for seamless oral ingestion or targeted localized vaginal placement based on clinical choice.

• Metabolic and Vascular Safety: Maintains a neutral impact on blood pressure profiles and beneficial HDL/LDL cholesterol fractions, preserving parallel cardiovascular therapies.

• Profound Somnolytic Relief: Capitalizes on natural GABA pathways when taken at night, directly resolving severe menopausal insomnia and nighttime restlessness.

• Therapeutic Application Protocol: The exact dosing schedule must be personalized by an endocrine or fertility specialist. For sequential HRT or cycle correction, it is frequently taken once daily at bedtime for a specific block of 12 to 14 days per month.

• Administration Protocols:

  • Oral Use: Take on an empty stomach immediately before retiring for the night to optimize absorption and align its natural sedative properties with sleep.

  • Vaginal Use: Insert the soft gel capsule deeply into the vaginal vault as directed for direct, localized reproductive tissue delivery.

• Storage Requirements: Store in a controlled, stable environment below 25°C. Keep the original blister packing intact to safeguard the soft gelatin structure from environmental humidity or heat.

• Common Oral Manifestations: Transient dizziness, noticeable evening drowsiness, abdominal bloating, breast tenderness, temporary fluid retention, or mild mood fluctuations during the initiation phase.

• Daytime Operational Warning: Because a 300mg oral dose delivers a strong calming effect on the nervous system, avoid driving, operating machinery, or participating in hazardous activities immediately following ingestion.

• Strict Contraindications: Contraindicated in individuals with active or a history of deep vein thrombosis (DVT), pulmonary embolism, undiagnosed abnormal vaginal bleeding, severe hepatic impairment, or known progestogen-dependent malignancies.